onfirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Sweden—the first to compare mortality rates among patients treated with individual TNF inhibitors—is now available in Arthritis & Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).
New data1 presented at the European League Against Rheumatism (EULAR) annual meeting revealed that when rheumatoid arthritis (RA) patients do not respond to a TNF inhibitor, a commonly used class of drugs in RA, it is more effective... Read Post
Humira (adalimumab) is a TNF inhibitor approved for the treatment of rheumatoid arthritis, chronic plaque psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. Humi... Read Post